ZYME
USDZymeworks Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$18.390
高値
$18.770
安値
$18.000
出来高
0.08M
企業ファンダメンタルズ
時価総額
1.4B
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
0.66M
取引所
NMS
通貨
USD
52週レンジ
関連ニュース
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
